The University of Chicago Header Logo

Janardan Khandekar

Concepts (428)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Colorectal Neoplasms
4
2026
1120
0.520
Why?
Community Pharmacy Services
1
2016
6
0.500
Why?
Community Health Planning
1
2016
23
0.500
Why?
Precision Medicine
4
2026
512
0.490
Why?
Professional Role
1
2016
40
0.480
Why?
Genetic Heterogeneity
1
2014
72
0.410
Why?
Patient Care Team
1
2016
318
0.400
Why?
Neoplasms
10
2026
3382
0.390
Why?
Pharmacogenetics
1
2016
474
0.370
Why?
DNA Glycosylases
1
2012
22
0.360
Why?
Adenomatous Polyposis Coli Protein
1
2012
42
0.360
Why?
Adenomatous Polyposis Coli
1
2012
44
0.360
Why?
Haplotypes
1
2014
657
0.350
Why?
Biomarkers, Tumor
3
2026
1786
0.350
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
3
2012
406
0.350
Why?
Antineoplastic Agents
11
2021
2386
0.340
Why?
Surveys and Questionnaires
3
2016
3058
0.320
Why?
Adenoma
1
2012
262
0.310
Why?
High-Throughput Nucleotide Sequencing
2
2026
588
0.310
Why?
Skin Neoplasms
7
2013
638
0.290
Why?
Breast Neoplasms
19
2013
3303
0.250
Why?
Thiophenes
1
2026
46
0.230
Why?
Quinazolines
2
2026
222
0.230
Why?
Clinical Trials, Phase I as Topic
1
2006
154
0.220
Why?
Humans
77
2026
98799
0.220
Why?
Aged
43
2026
21986
0.210
Why?
Middle Aged
49
2026
29642
0.200
Why?
Mutation
3
2023
4443
0.200
Why?
Female
55
2026
51997
0.190
Why?
Vascular Endothelial Growth Factor A
1
2005
402
0.190
Why?
Dietary Fats
4
2009
135
0.180
Why?
Prostatic Neoplasms
6
2016
1846
0.180
Why?
Postmenopause
7
2013
109
0.180
Why?
ErbB Receptors
1
2005
517
0.170
Why?
Sickle Cell Trait
1
2021
22
0.170
Why?
Outpatients
1
2021
107
0.160
Why?
Viral Load
1
2021
162
0.160
Why?
Venous Thromboembolism
1
2023
178
0.160
Why?
Biological Specimen Banks
1
2021
83
0.160
Why?
Reverse Transcriptase Polymerase Chain Reaction
2
2021
889
0.160
Why?
Thrombosis
1
2023
319
0.160
Why?
Protein Kinase Inhibitors
1
2005
642
0.160
Why?
Genital Neoplasms, Female
1
2021
118
0.150
Why?
Antibodies, Viral
1
2021
342
0.150
Why?
Patient Care Planning
2
2021
92
0.150
Why?
Male
36
2026
47475
0.150
Why?
Antibodies, Monoclonal
2
2005
1422
0.140
Why?
Prospective Studies
11
2026
4837
0.140
Why?
Neoplasm Recurrence, Local
9
2015
1538
0.130
Why?
Isotretinoin
1
2017
22
0.130
Why?
Ovarian Neoplasms
5
2007
829
0.130
Why?
Coronary Artery Disease
2
2012
391
0.130
Why?
Molecular Biology
1
1997
83
0.120
Why?
Genetic Testing
2
2021
610
0.120
Why?
Proportional Hazards Models
4
2016
925
0.120
Why?
Patient Education as Topic
2
2015
419
0.120
Why?
Ataxia Telangiectasia Mutated Proteins
1
2016
65
0.120
Why?
Dermatologic Agents
1
2017
81
0.120
Why?
Carcinoma
3
1995
442
0.120
Why?
Terminology as Topic
1
1997
226
0.110
Why?
BRCA2 Protein
1
2016
178
0.110
Why?
Aftercare
1
1996
93
0.110
Why?
Cisplatin
2
1990
578
0.110
Why?
BRCA1 Protein
1
2016
222
0.110
Why?
Carcinoma, Squamous Cell
2
2017
1107
0.110
Why?
Neoplasms, Second Primary
1
2017
244
0.110
Why?
Pleural Effusion, Malignant
1
1995
15
0.110
Why?
Pleura
1
1995
30
0.110
Why?
Adult
27
2026
29698
0.110
Why?
Melanoma
2
2012
523
0.110
Why?
Self Care
1
2015
188
0.100
Why?
Health Promotion
1
2015
175
0.100
Why?
Dysgerminoma
1
1993
7
0.100
Why?
Fallopian Tube Neoplasms
1
1993
39
0.100
Why?
Germ-Line Mutation
1
2016
404
0.100
Why?
Malpractice
1
1993
47
0.090
Why?
Patient-Centered Care
1
2015
233
0.090
Why?
Quality Indicators, Health Care
2
2012
158
0.090
Why?
Risk
3
2011
662
0.090
Why?
Adenocarcinoma
9
1994
1215
0.090
Why?
Molecular Targeted Therapy
2
2026
331
0.090
Why?
Risk Factors
7
2023
6295
0.090
Why?
Anthropometry
1
2011
77
0.090
Why?
Head and Neck Neoplasms
2
2017
1091
0.080
Why?
Breast
3
2010
317
0.080
Why?
Demography
1
2011
193
0.080
Why?
Total Quality Management
1
2011
31
0.080
Why?
Cardiopulmonary Bypass
1
2012
162
0.080
Why?
Chi-Square Distribution
1
2011
361
0.080
Why?
Lip Neoplasms
1
1990
10
0.080
Why?
Mass Screening
1
1996
753
0.080
Why?
Neoplasms, Multiple Primary
2
2004
100
0.080
Why?
Time Factors
6
2013
5586
0.080
Why?
Urinary Bladder Neoplasms
2
1993
403
0.080
Why?
Amygdalin
2
1980
3
0.080
Why?
Linoleic Acid
1
2009
5
0.080
Why?
Sensitivity and Specificity
3
2007
1946
0.080
Why?
Aged, 80 and over
7
2026
7461
0.080
Why?
Arachidonic Acid
1
2009
63
0.080
Why?
Eicosapentaenoic Acid
1
2009
22
0.080
Why?
Electronic Health Records
2
2012
456
0.080
Why?
Endothelium, Vascular
1
2012
440
0.070
Why?
Coronary Artery Bypass
1
2012
234
0.070
Why?
Docosahexaenoic Acids
1
2009
35
0.070
Why?
Decision Support Systems, Clinical
1
2011
135
0.070
Why?
Histone Deacetylase Inhibitors
1
2010
109
0.070
Why?
Anticarcinogenic Agents
1
2009
71
0.070
Why?
Antineoplastic Combined Chemotherapy Protocols
6
2007
2666
0.070
Why?
Practice Patterns, Physicians'
2
2012
669
0.070
Why?
Fluorouracil
4
2026
543
0.070
Why?
Quality Improvement
1
2012
538
0.070
Why?
CA-125 Antigen
1
2007
24
0.070
Why?
United States
5
2017
8387
0.070
Why?
Drug Evaluation
13
1989
109
0.060
Why?
alpha-Fetoproteins
1
2007
48
0.060
Why?
Neoplasms, Radiation-Induced
3
2001
96
0.060
Why?
Pancreatic Neoplasms
2
2007
782
0.060
Why?
DNA-Binding Proteins
2
2010
1275
0.060
Why?
Repressor Proteins
1
2010
450
0.060
Why?
Odds Ratio
3
2021
728
0.060
Why?
Internal Medicine
2
2011
337
0.060
Why?
Proto-Oncogene Proteins
1
2010
687
0.060
Why?
Thymidylate Synthase
1
2026
15
0.060
Why?
Teniposide
2
1986
6
0.060
Why?
Neoplasm Proteins
1
2009
553
0.060
Why?
Podophyllotoxin
2
1986
9
0.060
Why?
Urologic Neoplasms
2
1989
82
0.060
Why?
Women's Health
3
2013
120
0.060
Why?
Antibiotics, Antineoplastic
2
2001
111
0.060
Why?
Polymorphism, Single Nucleotide
1
2014
2577
0.060
Why?
Work Schedule Tolerance
1
2005
34
0.060
Why?
Follow-Up Studies
7
2017
4049
0.060
Why?
Nuclear Proteins
1
2010
757
0.060
Why?
Neoplasm Metastasis
10
2007
1102
0.060
Why?
Transcription, Genetic
1
2010
1136
0.060
Why?
Carcinoma, Transitional Cell
2
1989
158
0.060
Why?
Neoplasm Staging
7
2017
2087
0.060
Why?
Prostate-Specific Antigen
1
2007
356
0.060
Why?
Transcription Factors
2
2010
1724
0.050
Why?
Biomarkers
1
2012
2026
0.050
Why?
Feeding Behavior
1
2007
354
0.050
Why?
Personnel Staffing and Scheduling
1
2005
103
0.050
Why?
Endometrial Neoplasms
1
2007
243
0.050
Why?
Neoplasm Invasiveness
3
2009
583
0.050
Why?
Academic Medical Centers
1
2026
416
0.050
Why?
Progesterone Congeners
1
2003
4
0.050
Why?
Factor V
1
2023
10
0.050
Why?
Prothrombin
1
2023
19
0.050
Why?
Estrogens, Conjugated (USP)
1
2003
16
0.050
Why?
Liver Neoplasms
3
2007
840
0.050
Why?
Medroxyprogesterone Acetate
1
2003
23
0.050
Why?
Estrogen Replacement Therapy
1
2003
52
0.050
Why?
Carcinoma, Hepatocellular
1
2007
455
0.050
Why?
Diethylstilbestrol
2
1985
121
0.050
Why?
Predictive Value of Tests
1
2007
1792
0.050
Why?
Reminder Systems
2
2012
19
0.040
Why?
Preexisting Condition Coverage
1
2021
3
0.040
Why?
Hemangiosarcoma
1
2001
16
0.040
Why?
Hypoglycemia
1
1982
114
0.040
Why?
Menogaril
1
2001
3
0.040
Why?
Population
1
2021
36
0.040
Why?
Vascular Neoplasms
1
2001
21
0.040
Why?
Treatment Outcome
3
2012
9806
0.040
Why?
Neoplasms, Hormone-Dependent
1
2001
35
0.040
Why?
Thiadiazoles
2
1994
14
0.040
Why?
Neutropenia
1
2021
211
0.040
Why?
Prognosis
5
2017
4139
0.040
Why?
United Kingdom
1
2021
217
0.040
Why?
Rectal Neoplasms
3
1987
139
0.040
Why?
Thrombocytopenia
1
2021
194
0.040
Why?
Survival Analysis
3
2016
1530
0.040
Why?
Genomics
1
2026
914
0.040
Why?
Polycomb Repressive Complex 2
2
2010
32
0.040
Why?
Diabetes Complications
1
2021
176
0.040
Why?
Adenoma, Islet Cell
1
1979
28
0.040
Why?
Enhancer of Zeste Homolog 2 Protein
2
2010
41
0.040
Why?
Paraneoplastic Syndromes
1
1979
16
0.040
Why?
DNA Mutational Analysis
1
2021
554
0.040
Why?
Semustine
1
1979
2
0.040
Why?
Nitrosourea Compounds
1
1979
9
0.040
Why?
Central Nervous System Diseases
1
1979
36
0.040
Why?
Glucagon
1
1979
114
0.040
Why?
Neoplasm Seeding
1
1979
15
0.040
Why?
Mammography
1
2003
505
0.040
Why?
Glioblastoma
2
1996
301
0.040
Why?
Incidence
3
2012
1798
0.040
Why?
Cost-Benefit Analysis
2
1996
521
0.040
Why?
Nipples
1
1979
40
0.040
Why?
Methylation
2
2010
294
0.040
Why?
Combined Modality Therapy
6
1996
1754
0.040
Why?
Heat-Shock Proteins
1
1999
178
0.030
Why?
Down-Regulation
2
2010
529
0.030
Why?
Histones
2
2010
365
0.030
Why?
Physical Examination
3
1996
149
0.030
Why?
Carcinoma 256, Walker
2
1979
4
0.030
Why?
Animals
4
2014
29045
0.030
Why?
Colonic Neoplasms
3
1987
592
0.030
Why?
Antineoplastic Agents, Phytogenic
1
1998
272
0.030
Why?
Time
1
1977
80
0.030
Why?
Leukemia, Erythroblastic, Acute
1
1977
28
0.030
Why?
Carcinoma, Intraductal, Noninfiltrating
1
1978
137
0.030
Why?
Paclitaxel
1
1998
484
0.030
Why?
Mesothelioma
2
1995
342
0.030
Why?
Benzoquinones
2
1987
27
0.030
Why?
Medical History Taking
1
1996
81
0.030
Why?
Cerebellar Neoplasms
2
1987
44
0.030
Why?
Retrospective Studies
3
2021
11104
0.030
Why?
Brain Neoplasms
3
1996
845
0.030
Why?
Internship and Residency
1
2005
1132
0.030
Why?
Gene Expression
1
1999
1322
0.030
Why?
Transitional Care
1
2015
26
0.030
Why?
Neoplasm Grading
1
2016
425
0.030
Why?
Thoracotomy
1
1995
71
0.030
Why?
Health Care Costs
1
1996
269
0.030
Why?
Multiple Myeloma
1
1998
372
0.030
Why?
Drainage
1
1995
176
0.030
Why?
Survivors
1
2015
211
0.030
Why?
Survival Rate
2
1996
2057
0.030
Why?
Ambulatory Care
1
2015
203
0.020
Why?
Uterine Neoplasms
1
1978
289
0.020
Why?
Cell Line, Tumor
2
2010
2913
0.020
Why?
New Jersey
1
1993
7
0.020
Why?
Continuity of Patient Care
1
2015
180
0.020
Why?
Sunlight
1
2013
27
0.020
Why?
Dose-Response Relationship, Drug
4
2007
1949
0.020
Why?
Double-Blind Method
1
2017
1793
0.020
Why?
Sequence Analysis, DNA
1
2016
920
0.020
Why?
Radioisotope Teletherapy
1
1992
4
0.020
Why?
Mastectomy, Modified Radical
1
1992
6
0.020
Why?
Cobalt Radioisotopes
1
1992
19
0.020
Why?
Angiotensin Receptor Antagonists
1
2012
42
0.020
Why?
Reimbursement, Incentive
1
2012
37
0.020
Why?
Zoxazolamine
1
1972
2
0.020
Why?
Hexobarbital
1
1972
2
0.020
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2012
99
0.020
Why?
Creatine Kinase, MB Form
1
2012
7
0.020
Why?
Microsomes, Liver
1
1972
48
0.020
Why?
Risk Assessment
2
2012
2604
0.020
Why?
Case-Control Studies
1
2016
2017
0.020
Why?
Feedback
1
2012
132
0.020
Why?
Creatine Kinase
1
2012
51
0.020
Why?
Adrenergic beta-Antagonists
1
2012
112
0.020
Why?
Patient Compliance
1
1993
247
0.020
Why?
Age Factors
1
2016
1976
0.020
Why?
Vascular Cell Adhesion Molecule-1
1
2012
58
0.020
Why?
Phosphoric Acids
1
1971
5
0.020
Why?
Troponin I
1
2012
27
0.020
Why?
Lymphatic Metastasis
1
1993
519
0.020
Why?
Myocardium
2
2012
578
0.020
Why?
Insecticides
1
1971
26
0.020
Why?
Complement Activation
1
2012
88
0.020
Why?
Recurrence
1
1995
1274
0.020
Why?
Cyclophosphamide
4
1992
285
0.020
Why?
Drug Therapy, Combination
3
1983
766
0.020
Why?
Drug Administration Schedule
3
1998
837
0.020
Why?
Enzyme-Linked Immunosorbent Assay
1
2012
374
0.020
Why?
Vitamin D
1
2013
287
0.020
Why?
Decision Support Techniques
1
2012
193
0.020
Why?
Polycomb Repressive Complex 1
1
2010
7
0.020
Why?
Polycomb-Group Proteins
1
2010
10
0.020
Why?
Endoplasmic Reticulum
1
1972
258
0.020
Why?
Mitoguazone
1
1989
2
0.020
Why?
Ubiquitination
1
2010
80
0.020
Why?
Insulin-Like Growth Factor Binding Protein 3
1
2009
21
0.020
Why?
Documentation
1
2011
114
0.020
Why?
Insulin-Like Growth Factor Binding Proteins
1
2009
23
0.020
Why?
Vinblastine
1
1989
84
0.020
Why?
Point-of-Care Systems
1
2011
155
0.020
Why?
Linear Models
1
2011
428
0.020
Why?
Oxazoles
1
1989
14
0.020
Why?
Coronary Disease
1
2011
227
0.020
Why?
Proteasome Endopeptidase Complex
1
2009
112
0.020
Why?
Cellular Senescence
1
2010
113
0.020
Why?
Drug Prescriptions
1
2011
161
0.020
Why?
Aziridines
2
1987
10
0.020
Why?
Proto-Oncogene Proteins c-myc
1
2010
160
0.020
Why?
Program Evaluation
1
2011
349
0.020
Why?
Isoxazoles
1
1989
81
0.020
Why?
Lysine
1
2010
170
0.020
Why?
Diagnosis, Differential
1
1993
1571
0.020
Why?
Clinical Trials as Topic
6
1987
1128
0.020
Why?
Leukopenia
3
1985
66
0.020
Why?
Myocardial Infarction
1
2012
397
0.020
Why?
Cadherins
1
2009
189
0.020
Why?
Kidney Neoplasms
2
1985
556
0.020
Why?
Thyroid Neoplasms
2
1986
470
0.020
Why?
Edible Grain
1
2007
9
0.020
Why?
Length of Stay
1
2012
889
0.020
Why?
Vegetables
1
2007
50
0.020
Why?
Fruit
1
2007
82
0.020
Why?
Protein Processing, Post-Translational
1
2009
404
0.020
Why?
Liver
1
1972
1231
0.020
Why?
Acid Phosphatase
2
1985
28
0.020
Why?
Cystadenocarcinoma, Serous
1
2007
69
0.020
Why?
Carcinoma, Endometrioid
1
2007
60
0.020
Why?
Longitudinal Studies
1
2011
1305
0.020
Why?
Astrocytoma
1
1987
87
0.020
Why?
Deoxycytidine
1
2007
218
0.010
Why?
Epithelial Cells
1
2010
710
0.010
Why?
Chicago
1
2011
1520
0.010
Why?
Cohort Studies
1
2013
3242
0.010
Why?
Medulloblastoma
1
1986
44
0.010
Why?
Antimetabolites, Antineoplastic
1
2007
246
0.010
Why?
Azirines
1
1985
3
0.010
Why?
Lung Neoplasms
4
1995
2474
0.010
Why?
Weight Loss
1
2007
247
0.010
Why?
Radio Waves
1
1985
20
0.010
Why?
Germanium
1
1984
4
0.010
Why?
Medical Errors
1
2005
93
0.010
Why?
Anthraquinones
1
1984
9
0.010
Why?
Spiro Compounds
1
1984
24
0.010
Why?
Mitolactol
1
1984
1
0.010
Why?
Job Satisfaction
1
2005
87
0.010
Why?
Sleep Deprivation
1
2005
128
0.010
Why?
Fatigue
1
2005
187
0.010
Why?
Workload
1
2005
131
0.010
Why?
Hyperthermia, Induced
1
1985
77
0.010
Why?
BCG Vaccine
2
1984
44
0.010
Why?
Gene Expression Regulation, Neoplastic
1
2009
1400
0.010
Why?
Apoptosis
1
2010
1754
0.010
Why?
Diabetes Mellitus
1
2011
815
0.010
Why?
Burnout, Professional
1
2005
126
0.010
Why?
Organometallic Compounds
1
1984
142
0.010
Why?
Interferon Type I
1
1985
170
0.010
Why?
Adjuvants, Immunologic
1
1984
177
0.010
Why?
Mastectomy
3
1980
277
0.010
Why?
Thyroxine
1
1986
411
0.010
Why?
Evaluation Studies as Topic
1
1983
244
0.010
Why?
Indomethacin
1
1983
58
0.010
Why?
Glioma
1
1985
310
0.010
Why?
Regression Analysis
1
2004
578
0.010
Why?
Young Adult
1
2015
7598
0.010
Why?
Interferons
1
1983
114
0.010
Why?
Radiotherapy
2
1986
325
0.010
Why?
Carmustine
2
1996
70
0.010
Why?
Attitude
1
1983
134
0.010
Why?
Pheochromocytoma
1
1982
54
0.010
Why?
Fibrosarcoma
1
1982
90
0.010
Why?
Glucose Tolerance Test
1
1982
239
0.010
Why?
Energy Intake
2
1993
100
0.010
Why?
Adrenal Gland Neoplasms
1
1982
85
0.010
Why?
Monocytes
1
1983
219
0.010
Why?
Syndrome
1
1982
444
0.010
Why?
Depression
1
2005
625
0.010
Why?
Random Allocation
3
1986
312
0.010
Why?
Mastectomy, Segmental
1
2001
119
0.010
Why?
Pleural Neoplasms
1
1982
204
0.010
Why?
Drug Evaluation, Preclinical
1
1980
111
0.010
Why?
Postoperative Complications
1
2012
2719
0.010
Why?
Rodentia
1
1980
49
0.010
Why?
Heart Failure
1
2011
1508
0.010
Why?
Streptozocin
1
1979
56
0.010
Why?
Rats
2
1979
4079
0.010
Why?
Lymphedema
1
2001
92
0.010
Why?
Remission, Spontaneous
1
1979
45
0.010
Why?
Cyanides
1
1979
16
0.010
Why?
Drug Tolerance
1
1979
59
0.010
Why?
Sodium Chloride
1
1979
84
0.010
Why?
Infusions, Intravenous
2
1989
403
0.010
Why?
DNA Primers
1
1999
530
0.010
Why?
Gastrointestinal Neoplasms
1
1979
114
0.010
Why?
Physicians
1
2005
687
0.010
Why?
Granulocyte Colony-Stimulating Factor
1
1998
158
0.010
Why?
Doxorubicin
2
1992
285
0.010
Why?
Skin
1
2001
592
0.010
Why?
Transplantation, Autologous
1
1979
398
0.010
Why?
Bone Marrow
1
1979
419
0.010
Why?
Cross-Sectional Studies
1
2004
2077
0.010
Why?
Adolescent
4
1987
10168
0.010
Why?
Chlorambucil
1
1977
13
0.010
Why?
Quality of Life
1
2005
1904
0.010
Why?
Bone Neoplasms
3
1985
316
0.010
Why?
Long-Term Care
1
1977
69
0.010
Why?
Mitomycin
1
1996
30
0.010
Why?
Karnofsky Performance Status
1
1996
43
0.010
Why?
Mercaptopurine
1
1996
53
0.010
Why?
Cell Line
1
1999
2484
0.010
Why?
Quality Assurance, Health Care
1
1996
229
0.010
Why?
Vitamins
1
1993
93
0.010
Why?
Receptors, Estrogen
2
1984
431
0.010
Why?
Melphalan
2
1984
98
0.010
Why?
Benz(a)Anthracenes
1
1972
4
0.010
Why?
Body Weight
1
1993
457
0.010
Why?
Sarcoma, Experimental
1
1972
53
0.010
Why?
Paralysis
1
1972
33
0.010
Why?
Organophosphate Poisoning
1
1971
2
0.010
Why?
Poisoning
1
1971
41
0.010
Why?
Neoplasm Transplantation
1
1972
400
0.010
Why?
Microscopy, Electron
1
1972
435
0.010
Why?
Organ Size
1
1972
370
0.010
Why?
Feasibility Studies
1
1993
818
0.010
Why?
Multicenter Studies as Topic
1
1990
195
0.000
Why?
Postoperative Care
2
1980
239
0.000
Why?
Electrocardiography
1
1971
528
0.000
Why?
Dacarbazine
1
1987
104
0.000
Why?
Statistics as Topic
1
1987
229
0.000
Why?
Vincristine
1
1986
102
0.000
Why?
Cyclohexenes
1
1985
5
0.000
Why?
Gastrointestinal Diseases
1
1987
156
0.000
Why?
Castration
1
1985
32
0.000
Why?
Multi-Institutional Systems
1
1985
3
0.000
Why?
Thermal Conductivity
1
1985
4
0.000
Why?
Stomach Ulcer
1
1985
23
0.000
Why?
Nausea
1
1985
95
0.000
Why?
Randomized Controlled Trials as Topic
1
1989
995
0.000
Why?
Vomiting
1
1985
109
0.000
Why?
Body Temperature
1
1985
128
0.000
Why?
Leukocyte Count
1
1985
215
0.000
Why?
Mitoxantrone
1
1984
65
0.000
Why?
Child
2
1987
7771
0.000
Why?
Prednisolone
1
1984
38
0.000
Why?
Anemia
1
1985
135
0.000
Why?
Radiography
1
1985
763
0.000
Why?
Burns
1
1985
150
0.000
Why?
Phytohemagglutinins
1
1983
20
0.000
Why?
Pulmonary Fibrosis
1
1985
158
0.000
Why?
Pain Management
1
1985
198
0.000
Why?
Pain
1
1985
417
0.000
Why?
Cell Adhesion
1
1983
421
0.000
Why?
Cell Division
1
1983
690
0.000
Why?
Lymphocytes
1
1983
461
0.000
Why?
Maxillary Neoplasms
1
1980
7
0.000
Why?
Hematuria
1
1980
53
0.000
Why?
Thymus Gland
1
1979
205
0.000
Why?
Child, Preschool
1
1986
4053
0.000
Why?
Preoperative Care
1
1980
420
0.000
Why?
Immunotherapy
1
1983
831
0.000
Why?
Tomography, X-Ray Computed
1
1986
2680
0.000
Why?
Khandekar's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (428)
Explore
_
Co-Authors (19)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_